Result Update

Page Industries



Your success is our success

Refer to important disclosures at the end of this report

Exceeding growth expectations; upgrade to Buy

CMP Rs 31,764 as of (May 27, 2021)

Target Price Rs 36,500 (A)

Rating BUY (▲) **Upside** 14.9 %

- We upgrade PAG to Buy from Hold as the strong Q4 beat and management's aggressive growth initiatives provide confidence of robust growth momentum ahead. Step-up in growth plans for athleisure/women/kids portfolios, faster network ramp-up (incl. MBO/EBO addition) and focus on rural penetration offer an improved mid-teens growth outlook.
- Q4 performance exceeded expectations. Sales grew 63% to Rs8.8bn (8% beat), led by 53% volume growth. Growth in EBITDA/PAT was in line with estimates and was impacted by higher overhead spends, up 37%, which should normalize ahead.
- Excluding the lockdown impact in Q1FY22, management commentary pointed to a strong growth outlook. Secondary growth was higher vs. primary in Q4. Margins are expected to remain stable as the 4-5% price hike effected in Apr'21 is likely to offset the input inflation.
- Factoring in the strong revenue run rate in Q3/Q4, we raise our FY23 estimates by 15%. FY22E EPS is unchanged due to the lockdown impact. We raise the TP to Rs36,500, valuing PAG at 55x Jun'23E EPS (vs. 50x earlier) supported by DCF working.

Aggressive product and distribution expansion plans improve growth outlook: PAG's strong beat in Q4 and aggressive growth plans provide increased confidence of better growth momentum ahead. PAG's stronger growth was led by 1) acceleration in athleisure growth, which should continue; 2) aggressive growth plans for women and kids juniors with increased focus from separate sales teams; 3) faster ramp-up in distribution, including MBO's/EBO's (added 12k+ MBO and 180 EBO's), special focus on rural and increasing contribution from ecommerce (up from 4% to 8%); and 4) improved supply chain (ARS implementation 90% covered) providing better sales efficiencies. Management appeared confident of sustaining growth momentum post the lockdown impact in Q1FY22.

Q4 performance exceeded expectations: PAG recorded 63% growth in Q4, led by healthy 53% volume growth. Distribution expansion was healthy with ~14,000 MBO additions (up ~18%) and 180 EBO additions (up ~29%) in FY21. Manufacturing operations are currently suspended but PAG expects a quick recovery post unlocking, based on strong supply chain and last year's learnings. EBITDA margins at 19.3% were up 850bps YoY but declined sequentially due to higher ad/corporate overheads (up 37%). Gross margins improved 220bps on low-priced inventory. Price hikes of 4-5% effected in Apr'21 is expected to offset input inflation. Working capital saw strong improvement to ~6% of sales (vs. 15% of sales in FY20).

Increase earnings by 15%; upgrade to Buy: Factoring in the improved revenue run rate in Q3/Q4, we increase our FY23 forecasts by 15%. FY22 estimates remain largely unchanged due to the lockdown impact in Q1. With supply chain issues behind, PAG's stronger product expansion plans and faster increase in distribution offer better visibility of mid-teens growth sustaining ahead. Valuations at 50x FY23E are at a discount to other high growth peers. We, hence, upgrade the stock to Buy and raise the TP to Rs36,500, (from Rs28,000) based on 55x Jun'23E EPS (vs. 50x Mar'23 earlier).

Please see our sector model portfolio (Emkay Alpha Portfolio): Consumer Goods & Retail (page 8)

Financial Snapshot (Standalone)

. ,	,				
(Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	29,454	28,356	37,153	44,764	51,341
EBITDA	5,326	5,292	7,772	10,053	11,712
EBITDA Margin (%)	18.1	18.7	20.9	22.5	22.8
APAT	3,432	3,432	5,308	7,023	8,222
EPS (Rs)	307.7	307.7	475.9	629.6	737.1
EPS (% chg)	(12.9)	0.0	54.7	32.3	17.1
ROE (%)	43.0	40.3	54.8	59.6	56.3
P/E (x)	103.2	103.2	66.8	50.4	43.1
EV/EBITDA (x)	66.3	66.1	45.0	34.7	29.6
P/BV (x)	43.2	40.0	33.7	27.1	22.0

Source: Company, Emkay Research

Change in Estimates	
EPS Chg FY22E/FY23E (%)	(1)/15
Target Price change (%)	30.4
Target Period (Months)	12
Previous Reco	HOLD

Emkay vs Consensus

CF	3 E	Sun	iale	5

	FY22E	FY23E
Emkay	475.9	629.6
Consensus	459.9	550.5
Mean Consensus TP (12M) F	Rs 28,388

Stock Details

Bloomberg Code	PAG IN
Face Value (Rs)	10
Shares outstanding (mn)	11
52 Week H/L	32,460 / 17,636
M Cap (Rs bn/USD bn)	354 / 4.88
Daily Avg Volume (nos.)	38,394
Daily Avg Turnover (US\$	mn) 15.6

Shareholding Pattern Mar '21

Promoters	48.3%
FIIs	25.9%
DIIs	15.5%
Public and Others	10.3%

Price Performance

(%)	1M	3M	6M	12M
Absolute	5	13	40	71
Rel. to Nifty	-	7	18	4

Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Ashit Desai

ashit.desai@emkayglobal.com


+91 22 6612 1340

Devanshu Bansal

devanshu.bansal@emkayglobal.com +91 22 6612 1385


Story in Charts

Exhibit 1: Best-ever Q4, led by expansion and emerging channels




Source: Company, Emkay Research

Exhibit 3: Athleisure, Kids and E-Com are driving volume growth




Source: Company, Emkay Research

Exhibit 5: MBO network addition has picked up in FY21




Source: Company, Emkay Research, * PPT reported gross margins

Exhibit 7: Working capital seeing sharp reduction




Source: Company, Emkay Research

Exhibit 2: EBITDA margins largely recovered to Q4FY19 levels




Source: Company, Emkay Research

Exhibit 4: Higher Ad/overheads led to increase in other costs




Source: Company, Emkay Research

Exhibit 6: Pace of EBO expansion has accelerated



Source: Company, Emkay Research

Exhibit 8: Page 1-Yr forward PE chart



Source: Company, Emkay Research

Exhibit 9: Actual vs. Estimates (Q4FY21)

Rs mn	Actual	Estimates	Consensus	% Var	iation	Comment
NS IIIII	Actual	(Emkay)	Estimates	Emkay	Consensus	Comment
Revenues	8,808	8,188	7,842	7.6%	12.3%	Revenues beat was led by higher volumes
EBITDA	1,698	1,792	1,701	-5.3%	-0.2%	
EBITDA margin (%)	19.3%	21.9%	21.7%	-261	-242	Higher operating expenses led to lower margins
APAT	1,155	1,201	1,131	-3.8%	2.1%	

Source: Company, Emkay Research

Exhibit 10: Quarterly performance (standalone)

Y/E, Mar (Rs mn)	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	YoY (%)	QoQ (%)	FY20	FY21	Gr (%)
Operating Income	5,413	2,848	7,403	9,271	8,808	62.7	-5.0	29,454	28,329	-3.8
Expenditure	4,831	3,195	5,749	7,009	7,110	47.2	1.4	24,128	23,063	-4.4
Consumption of RM	2,228	1,478	3,297	4,131	3,733	67.5	-9.6	13,108	12,639	-3.6
as % of sales	41.2	51.9	44.5	44.6	42.4			44.5	44.6	
Employee Cost	1,344	1,229	1,299	1,462	1,648	22.7	12.8	5,317	5,638	6.0
as % of sales	24.8	43.1	17.5	15.8	18.7			18.1	19.9	
Other expenditure	1,260	488	1,153	1,417	1,729	37.2	22.0	5,703	4,787	-16.1
as % of sales	23.3	17.1	15.6	15.3	19.6			19.4	16.9	
EBITDA	581	-347	1,654	2,261	1,698	192.1	-24.9	5,326	5,266	-1.1
Depreciation	163	160	157	156	156	-4.4	-0.3	614	629	2.5
EBIT	418	-508	1,497	2,105	1,542	268.7	-26.7	4,712	4,637	-1.6
Other Income	99	61	37	42	56	-43.9	33.9	246	195	-21.0
Interest	85	77	75	74	72	-16.2	-3.1	339	297	-12.2
PBT	432	-524	1,459	2,073	1,526	253.4	-26.4	4,620	4,534	-1.9
Total Tax	122	-128	350	536	371	204.8	-30.8	1,188	1,128	-5.0
APAT	310	-396	1,109	1,537	1,156	272.4	-24.8	3,432	3,406	-0.8
Minority Interest	0	0	0	0	0			0	0	
APAT (after minority)	310	-396	1,109	1,537	1,156	272.4	-24.8	3,432	3,406	-0.8
Extraordinary Items	0	0	0	0	0			0	0	
Reported PAT	310	-396	1,109	1,537	1,156	272.4	-24.8	3,432	3,406	-0.8
Adjusted EPS	27.8	-35.5	99.4	137.8	103.6	272.4	-24.8	307.7	305.3	-0.8

Margins (%)						(bps)	(bps)			(bps)
Gross margin	58.8	48.1	55.5	55.4	57.6	-120	220	55.5	55.4	-10
EBIDTA	10.7	-12.2	22.3	24.4	19.3	850	-510	18.1	18.6	50
EBIT	7.7	-17.9	20.2	22.7	17.5	980	-520	16.0	16.4	40
EBT	8.0	-18.4	19.7	22.4	17.3	930	-500	15.7	16.0	30
PAT	5.7	-13.9	15.0	16.6	13.1	740	-350	11.7	12.0	40
Effective Tax rate	28.1	24.4	24.0	25.8	24.3	-380	-150	25.7	24.9	-80

Source: Company, Emkay Research

Exhibit 11: Changes in estimates

V/E May (Ba mm)		FY22E			FY23E		FY24E		
Y/E Mar (Rs mn)	Earlier	Revised	% Change	Earlier	Revised	% Change	Introduced		
Revenues	35,883	37,153	3.5	40,287	44,764	11.1	51,341		
EBITDA	8,105	7,772	(4.1)	9,219	10,053	9.0	11,712		
EBITDA Margin (%)	22.6	20.9	-170 bps	22.9	22.5	-40 bps	22.8		
APAT	5,383	5,308	(1.4)	6,125	7,023	14.7	8,222		
EPS (Rs)	482.6	475.9	(1.4)	549.1	629.6	14.7	737.1		

Source: Company, Emkay Research

Exhibit 12: Peer comparison

Commonico	Price	Price Mcap		Target		EPS (Rs)			P/E (x)		EV / EBITDA (x)		
Companies	(Rs)	(Rs bn)	Reco	Reco Price (Rs)	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
ABFRL	186	170	Buy	206	-5.7	2.6	3.7	-32.5	72.3	50.1	65.9	11.9	9.9
Jubilant FoodWorks	3,096	415	Buy	2,750	18.0	44.6	54.5	171.8	69.4	56.8	53.4	32.4	27.2
Page Industries	31,764	355	Hold	28,000	307.7	475.9	629.6	103.2	66.8	50.4	66.3	45.1	34.8
Shoppers Stop	222	25	Hold	230	-23.1	-7.8	6.9	-9.6	-28.3	32.1	81.6	18.2	7.0
Titan Company	1,594	1,405	Buy	1,725	11.0	25.6	32.8	145.3	62.2	48.6	79.6	39.6	31.3
Westlife Development	487	73	Buy	600	-6.7	0.0	4.0	-73.1	9973.8	121.0	131.9	38.0	23.1

Source: Company, Emkay Research

Concall Highlights

- In terms of categories, volume growth was led by Athleisure/Junior/E-Com categories, while innerwear volumes were flat to slightly negative in FY21.
- For the core innerwear category, PAG highlighted healthy penetration improvement scope as it is currently only catering to ~20% addressable men's innerwear market and 6-8% in women's innerwear market.
- Kids and E-com businesses saw 75-80% growth in FY21 and share of E-commerce rose to ~8% in FY21 (vs. 4% in FY20). PAG expects new categories viz. Kids, Athleisure, E-Com to drive strong growth. In Kids category, PAG currently has 38 kids specific 'Jockey-Junior' EBOs and is also catering to 50 cities through MBOs.
- Management highlighted increased focus on tier-2/3 towns and on rural opportunity. It has created a rural portfolio of ~30 products from existing portfolio. Will focus on value for money and sustainability of distributor ROI.
- EBITDA margins for online e-commerce business are higher than the company average, while margins for kids business were indicated to be slightly lower.
- On the increase in Input inflation, PAG did not indicate much concerns and expects to negate the impact with price hikes. PAG took a price hike of 4-5% in April-21 (vs. 3-4% historically). Expect inflation may moderate again due to lower demand during recent lockdown
- New CEO Mr V S Ganesh expects the transition to be smooth with him being an incumbent for seven years and PAG having a strong culture and team.
- Net Cash equivalents stood at Rs4.4bn (vs. Rs0.9bn at FY20-end). Improvement was led by a profit recovery (Rs3.4bn in FY20/21), reduction of working capital and low capex (Rs0.2bn in FY21). PAG paid ~Rs2.8bn in dividends, Rs1.3bn as tax and retired Rs0.3bn debt in FY21.
- PAG stated that ~90% of its network is now on ARS. Distributors are finding ARS to be beneficial and ARS is helping to improve the Rol.

Key Financials (Standalone)

Income Statement

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	29,454	28,356	37,153	44,764	51,341
Expenditure	24,128	23,064	29,382	34,711	39,629
EBITDA	5,326	5,292	7,772	10,053	11,712
Depreciation	614	629	696	766	861
EBIT	4,712	4,663	7,076	9,288	10,851
Other Income	246	195	246	296	355
Interest expenses	339	297	227	194	214
PBT	4,620	4,560	7,096	9,389	10,992
Tax	1,188	1,128	1,788	2,366	2,770
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	3,432	3,432	5,308	7,023	8,222
Adjusted PAT	3,432	3,432	5,308	7,023	8,222

Balance Sheet

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Equity share capital	112	112	112	112	112
Reserves & surplus	8,087	8,737	10,405	12,948	16,018
Net worth	8,199	8,849	10,517	13,060	16,130
Minority Interest	0	0	0	0	0
Loan Funds	1,652	1,270	1,328	1,408	1,460
Net deferred tax liability	2	0	0	0	0
Total Liabilities	9,853	10,119	11,844	14,468	17,590
Net block	4,055	3,863	4,267	4,802	5,241
Investment	0	0	0	0	0
Current Assets	10,787	12,857	15,154	18,066	21,973
Cash & bank balance	1,169	4,350	4,568	5,066	7,345
Other Current Assets	0	0	0	0	0
Current liabilities & Provision	5,277	6,879	7,855	8,678	9,903
Net current assets	5,510	5,978	7,298	9,388	12,071
Misc. exp	0	0	0	0	0
Total Assets	9,853	10,119	11,844	14,468	17,590

Cash Flow

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
PBT (Ex-Other income) (NI+Dep)	4,620	4,534	7,096	9,389	10,992
Other Non-Cash items	0	0	0	0	0
Chg in working cap	741	2,713	(1,103)	(1,591)	(404)
Operating Cashflow	4,755	6,848	4,881	6,096	8,538
Capital expenditure	(564)	(228)	(800)	(1,000)	(1,000)
Free Cash Flow	4,192	6,621	4,081	5,096	7,538
Investments	0	0	0	0	0
Other Investing Cash Flow	0	0	0	0	0
Investing Cashflow	(317)	(33)	(554)	(704)	(645)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	(457)	(268)	70	70	70
Dividend paid (incl tax)	(2,716)	(2,789)	(3,640)	(4,480)	(5,152)
Other Financing Cash Flow	(355)	(438)	(490)	(483)	(532)
Financing Cashflow	(3,709)	(3,634)	(4,110)	(4,893)	(5,614)
Net chg in cash	729	3,181	218	498	2,279
Opening cash position	440	1,169	4,350	4,568	5,066
Closing cash position	1,169	4,350	4,568	5,066	7,345

Source: Company, Emkay Research

Key Ratios

Profitability (%)	FY20	FY21	FY22E	FY23E	FY24E
EBITDA Margin	18.1	18.7	20.9	22.5	22.8
EBIT Margin	16.0	16.4	19.0	20.7	21.1
Effective Tax Rate	25.7	24.7	25.2	25.2	25.2
Net Margin	11.7	12.1	14.3	15.7	16.0
ROCE	60.2	56.3	75.6	81.3	76.8
ROE	43.0	40.3	54.8	59.6	56.3
RoIC	57.2	67.2	113.3	115.2	113.7

Per Share Data (Rs)	FY20	FY21	FY22E	FY23E	FY24E
EPS	307.7	307.7	475.9	629.6	737.1
CEPS	362.7	364.1	538.2	698.3	814.3
BVPS	735.1	793.3	942.9	1,170.8	1,446.1
DPS	202.0	250.0	326.3	401.6	461.9

Valuations (x)	FY20	FY21	FY22E	FY23E	FY24E
PER	103.2	103.2	66.8	50.4	43.1
P/CEPS	88.0	87.7	59.3	45.7	39.2
P/BV	43.2	40.0	33.7	27.1	22.0
EV / Sales	12.2	12.6	9.6	7.9	6.9
EV / EBITDA	66.3	66.1	45.0	34.7	29.6
Dividend Yield (%)	0.6	0.8	1.0	1.3	1.5

Gearing Ratio (x)	FY20	FY21	FY22E	FY23E	FY24E
Net Debt/ Equity	(0.1)	(0.5)	(0.4)	(0.4)	(0.5)
Net Debt/EBIDTA	(0.2)	(0.8)	(0.6)	(0.5)	(0.6)
Working Cap Cycle (days)	53.8	21.0	26.8	35.2	33.6

Growth (%)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	3.3	(3.7)	31.0	20.5	14.7
EBITDA	(13.7)	(0.6)	46.9	29.4	16.5
EBIT	(19.6)	(1.0)	51.8	31.3	16.8
PAT	(12.9)	0.0	54.7	32.3	17.1

Quarterly (Rs mn)	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21
Revenue	5,413	2,848	7,403	9,271	8,808
EBITDA	581	(348)	1,653	2,261	1,698
EBITDA Margin (%)	10.7	(12.2)	22.3	24.4	19.3
PAT	310	(396)	1,109	1,537	1,155
EPS (Rs)	27.8	(35.5)	99.4	137.8	103.6

Source: Company, Emkay Research

Shareholding Pattern (%)	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21
Promoters	48.3	48.3	48.3	48.3	48.3
Fils	29.2	25.5	25.2	25.3	25.9
DIIs	10.0	13.4	14.8	15.5	15.5
Public and Others	12.5	12.8	11.7	10.8	10.3

Source: Capitaline

RECOMMENDATION HISTORY TABLE

RECOMMENDAT	ion morent				
Date	Closing Price	TP	Period (months)	Rating	Analyst
11-Feb-21	30,606	28,000	12m	Hold	Ashit Desai
13-Nov-20	21,715	19,250	12m	Hold	Ashit Desai
03-Sep-20	18,980	17,800	12m	Hold	Ashit Desai
24-Jun-20	20,556	17,500	12m	Hold	Ashit Desai
14-Apr-20	16,340	18,200	12m	Hold	Ashit Desai
08-Apr-20	16,597	18,200	12m	Hold	Ashit Desai
14-Feb-20	22,176	21,500	12m	Hold	Ashit Desai
25-Dec-19	21,665	23,000	12m	Hold	Ashit Desai
15-Nov-19	23,421	23,000	12m	Hold	Ashit Desai
20-Sep-19	22,309	22,200	12m	Hold	Ashit Desai
08-Aug-19	18,165	18,400	12m	Hold	Ashit Desai
24-May-19	21,524	23,000	12m	Hold	Ashit Desai
09-Apr-19	24,107	26,000	12m	Hold	Ashit Desai
14-Feb-19	23,404	26,000	12m	Hold	Ashit Desai
15-Nov-18	24,834	26,600	12m	Hold	Ashit Desai
13-Aug-18	31,383	30,500	12m	Hold	Ashit Desai

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Emkay Alpha Portfolio - Consumer Goods & Retail





Analyst: Ashit Desai

Contact Details

ashit.desai@emkayglobal.com +91 22 6612 1340

Sector

Consumer Goods & Retail

Analyst bio

Ashit Desai holds a PGDM and FRM (US GARP) with 12 years of research experience on the sell side. His team currently covers 24 stocks in the Indian Consumer and Retail space.

EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Consumer Goods & Retail	10.67	10.67	0%	0	100.00
Asian Paints	1.52	0.62	-60%	-91	5.77
Berger Paints	0.23	0.00	-100%	-23	0.00
Britannia Industries	0.46	0.51	10%	5	4.79
Colgate-Palmolive	0.26	0.31	21%	5	2.93
Dabur India	0.35	0.32	-6%	-2	3.04
Emami	0.12	0.16	26%	3	1.45
Godrej Consumer Products	0.36	0.37	4%	2	3.51
Hindustan Unilever	2.42	1.88	-22%	-54	17.61
ITC	2.11	2.20	4%	8	20.61
Marico	0.27	0.27	1%	0	2.57
Nestle India	0.72	0.64	-11%	-8	6.01
Pidilite Industries	0.37	0.00	-100%	-37	0.00
Radico Khaitan	0.00	0.35	NA	35	3.26
United Breweries	0.10	0.55	441%	45	5.20
United Spirits	0.00	0.35	NA	35	3.28
Varun Beverages	0.11	0.15	39%	4	1.45
ABFRL	0.06	0.16	148%	10	1.51
Jubilant FoodWorks	0.22	0.27	21%	5	2.54
Page Industries	0.21	0.24	15%	3	2.24
Shoppers Stop	0.00	0.00	NA	0	0.00
Titan Company	0.76	1.03	35%	27	9.64
Westlife Development	0.00	0.27	NA	27	2.58
Cash	0.00	0.00	NA	0	0.00

Source: Emkay Research

Sector portfolio NAV

Base						Latest
	1-Apr-19	29-May-20	25-Nov-20	24-Feb-21	26-Apr-21	26-May-21
EAP - Consumer Goods & Retail	100.0	100.6	109.1	117.0	118.8	125.5
BSE200 Neutral Weighted Portfolio (ETF)	100.0	95.5	104.8	111.2	114.8	121.1

^{*}Performance measurement base date 1st April 2019


Source: Emkay Research

Price Performance (%)

	1m	3m	6m	12m
EAP - Consumer Goods & Retail	5.7%	7.3%	15.1%	24.7%
BSE200 Neutral Weighted Portfolio (ETF)	5.5%	8.9%	15.5%	26.8%

Source: Emkay Research

NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

^{*} Not under coverage: Equal Weight

[■] High Conviction/Strong Over Weight ■ High Conviction/Strong Under Weight

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	

Completed Date: 28 May 2021 05:34:23 (SGT) Dissemination Date: 28 May 2021 05:35:23 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayqlobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on the sender. Further, this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of May 28, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of May 28, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 28, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the May 28, 2021

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

RESTRICTIONS ON DISTRIBUTION

RESTRICTIONS ON L	NOTITIES TION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com